The global market for Rituximab Biosimilars is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Rituximab Biosimilars market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Rituximab Biosimilars market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Rituximab Biosimilars market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Rituximab Biosimilars market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Rituximab Biosimilars players cover Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals and Celltrion, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Rituximab Biosimilars market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Rituximab Biosimilars market, with both quantitative and qualitative data, to help readers understand how the Rituximab Biosimilars market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Rituximab Biosimilars market and forecasts the market size by Type (500mg, 100mg and Other), by Application (Hospital Pharmacy and Retail Pharmacy.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
500mg
100mg
Other
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy's Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
Chapter Introduction
Chapter 1: Scope of Rituximab Biosimilars, Research Methodology, etc.
Chapter 2: Executive Summary, global Rituximab Biosimilars market size (sales and revenue) and CAGR, Rituximab Biosimilars market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Rituximab Biosimilars sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Rituximab Biosimilars sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Rituximab Biosimilars market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy's Laboratories, Teva, Hetero Group and Innovent Biologics, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Rituximab Biosimilars Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Rituximab Biosimilars by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Rituximab Biosimilars by Country/Region, 2017, 2022 & 2028
2.2 Rituximab Biosimilars Segment by Type
2.2.1 500mg
2.2.2 100mg
2.2.3 Other
2.3 Rituximab Biosimilars Sales by Type
2.3.1 Global Rituximab Biosimilars Sales Market Share by Type (2017-2022)
2.3.2 Global Rituximab Biosimilars Revenue and Market Share by Type (2017-2022)
2.3.3 Global Rituximab Biosimilars Sale Price by Type (2017-2022)
2.4 Rituximab Biosimilars Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.5 Rituximab Biosimilars Sales by Application
2.5.1 Global Rituximab Biosimilars Sale Market Share by Application (2017-2022)
2.5.2 Global Rituximab Biosimilars Revenue and Market Share by Application (2017-2022)
2.5.3 Global Rituximab Biosimilars Sale Price by Application (2017-2022)
3 Global Rituximab Biosimilars by Company
3.1 Global Rituximab Biosimilars Breakdown Data by Company
3.1.1 Global Rituximab Biosimilars Annual Sales by Company (2020-2022)
3.1.2 Global Rituximab Biosimilars Sales Market Share by Company (2020-2022)
3.2 Global Rituximab Biosimilars Annual Revenue by Company (2020-2022)
3.2.1 Global Rituximab Biosimilars Revenue by Company (2020-2022)
3.2.2 Global Rituximab Biosimilars Revenue Market Share by Company (2020-2022)
3.3 Global Rituximab Biosimilars Sale Price by Company
3.4 Key Manufacturers Rituximab Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Rituximab Biosimilars Product Location Distribution
3.4.2 Players Rituximab Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Rituximab Biosimilars by Geographic Region
4.1 World Historic Rituximab Biosimilars Market Size by Geographic Region (2017-2022)
4.1.1 Global Rituximab Biosimilars Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Rituximab Biosimilars Annual Revenue by Geographic Region
4.2 World Historic Rituximab Biosimilars Market Size by Country/Region (2017-2022)
4.2.1 Global Rituximab Biosimilars Annual Sales by Country/Region (2017-2022)
4.2.2 Global Rituximab Biosimilars Annual Revenue by Country/Region
4.3 Americas Rituximab Biosimilars Sales Growth
4.4 APAC Rituximab Biosimilars Sales Growth
4.5 Europe Rituximab Biosimilars Sales Growth
4.6 Middle East & Africa Rituximab Biosimilars Sales Growth
5 Americas
5.1 Americas Rituximab Biosimilars Sales by Country
5.1.1 Americas Rituximab Biosimilars Sales by Country (2017-2022)
5.1.2 Americas Rituximab Biosimilars Revenue by Country (2017-2022)
5.2 Americas Rituximab Biosimilars Sales by Type
5.3 Americas Rituximab Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Rituximab Biosimilars Sales by Region
6.1.1 APAC Rituximab Biosimilars Sales by Region (2017-2022)
6.1.2 APAC Rituximab Biosimilars Revenue by Region (2017-2022)
6.2 APAC Rituximab Biosimilars Sales by Type
6.3 APAC Rituximab Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Rituximab Biosimilars by Country
7.1.1 Europe Rituximab Biosimilars Sales by Country (2017-2022)
7.1.2 Europe Rituximab Biosimilars Revenue by Country (2017-2022)
7.2 Europe Rituximab Biosimilars Sales by Type
7.3 Europe Rituximab Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Rituximab Biosimilars by Country
8.1.1 Middle East & Africa Rituximab Biosimilars Sales by Country (2017-2022)
8.1.2 Middle East & Africa Rituximab Biosimilars Revenue by Country (2017-2022)
8.2 Middle East & Africa Rituximab Biosimilars Sales by Type
8.3 Middle East & Africa Rituximab Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Rituximab Biosimilars
10.3 Manufacturing Process Analysis of Rituximab Biosimilars
10.4 Industry Chain Structure of Rituximab Biosimilars
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Rituximab Biosimilars Distributors
11.3 Rituximab Biosimilars Customer
12 World Forecast Review for Rituximab Biosimilars by Geographic Region
12.1 Global Rituximab Biosimilars Market Size Forecast by Region
12.1.1 Global Rituximab Biosimilars Forecast by Region (2023-2028)
12.1.2 Global Rituximab Biosimilars Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Rituximab Biosimilars Forecast by Type
12.7 Global Rituximab Biosimilars Forecast by Application
13 Key Players Analysis
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Rituximab Biosimilars Product Offered
13.1.3 Amgen Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AryoGen Pharmed
13.2.1 AryoGen Pharmed Company Information
13.2.2 AryoGen Pharmed Rituximab Biosimilars Product Offered
13.2.3 AryoGen Pharmed Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AryoGen Pharmed Main Business Overview
13.2.5 AryoGen Pharmed Latest Developments
13.3 Biocad
13.3.1 Biocad Company Information
13.3.2 Biocad Rituximab Biosimilars Product Offered
13.3.3 Biocad Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Biocad Main Business Overview
13.3.5 Biocad Latest Developments
13.4 Cadila Pharmaceuticals
13.4.1 Cadila Pharmaceuticals Company Information
13.4.2 Cadila Pharmaceuticals Rituximab Biosimilars Product Offered
13.4.3 Cadila Pharmaceuticals Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Cadila Pharmaceuticals Main Business Overview
13.4.5 Cadila Pharmaceuticals Latest Developments
13.5 Celltrion
13.5.1 Celltrion Company Information
13.5.2 Celltrion Rituximab Biosimilars Product Offered
13.5.3 Celltrion Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Celltrion Main Business Overview
13.5.5 Celltrion Latest Developments
13.6 Dr Reddy's Laboratories
13.6.1 Dr Reddy's Laboratories Company Information
13.6.2 Dr Reddy's Laboratories Rituximab Biosimilars Product Offered
13.6.3 Dr Reddy's Laboratories Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Dr Reddy's Laboratories Main Business Overview
13.6.5 Dr Reddy's Laboratories Latest Developments
13.7 Teva
13.7.1 Teva Company Information
13.7.2 Teva Rituximab Biosimilars Product Offered
13.7.3 Teva Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Teva Main Business Overview
13.7.5 Teva Latest Developments
13.8 Hetero Group
13.8.1 Hetero Group Company Information
13.8.2 Hetero Group Rituximab Biosimilars Product Offered
13.8.3 Hetero Group Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Hetero Group Main Business Overview
13.8.5 Hetero Group Latest Developments
13.9 Innovent Biologics
13.9.1 Innovent Biologics Company Information
13.9.2 Innovent Biologics Rituximab Biosimilars Product Offered
13.9.3 Innovent Biologics Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Innovent Biologics Main Business Overview
13.9.5 Innovent Biologics Latest Developments
13.10 Intas Biopharmaceuticals
13.10.1 Intas Biopharmaceuticals Company Information
13.10.2 Intas Biopharmaceuticals Rituximab Biosimilars Product Offered
13.10.3 Intas Biopharmaceuticals Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Intas Biopharmaceuticals Main Business Overview
13.10.5 Intas Biopharmaceuticals Latest Developments
13.11 Mylan
13.11.1 Mylan Company Information
13.11.2 Mylan Rituximab Biosimilars Product Offered
13.11.3 Mylan Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Mylan Main Business Overview
13.11.5 Mylan Latest Developments
13.12 Probiomed
13.12.1 Probiomed Company Information
13.12.2 Probiomed Rituximab Biosimilars Product Offered
13.12.3 Probiomed Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Probiomed Main Business Overview
13.12.5 Probiomed Latest Developments
13.13 TRPharma
13.13.1 TRPharma Company Information
13.13.2 TRPharma Rituximab Biosimilars Product Offered
13.13.3 TRPharma Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 TRPharma Main Business Overview
13.13.5 TRPharma Latest Developments
13.14 Zenotech Laboratories
13.14.1 Zenotech Laboratories Company Information
13.14.2 Zenotech Laboratories Rituximab Biosimilars Product Offered
13.14.3 Zenotech Laboratories Rituximab Biosimilars Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Zenotech Laboratories Main Business Overview
13.14.5 Zenotech Laboratories Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Rituximab Biosimilars Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Rituximab Biosimilars Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of 500mg
Table 4. Major Players of 100mg
Table 5. Major Players of Other
Table 6. Global Rituximab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 7. Global Rituximab Biosimilars Sales Market Share by Type (2017-2022)
Table 8. Global Rituximab Biosimilars Revenue by Type (2017-2022) & ($ million)
Table 9. Global Rituximab Biosimilars Revenue Market Share by Type (2017-2022)
Table 10. Global Rituximab Biosimilars Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Rituximab Biosimilars Sales by Application (2017-2022) & (K Units)
Table 12. Global Rituximab Biosimilars Sales Market Share by Application (2017-2022)
Table 13. Global Rituximab Biosimilars Revenue by Application (2017-2022)
Table 14. Global Rituximab Biosimilars Revenue Market Share by Application (2017-2022)
Table 15. Global Rituximab Biosimilars Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Rituximab Biosimilars Sales by Company (2020-2022) & (K Units)
Table 17. Global Rituximab Biosimilars Sales Market Share by Company (2020-2022)
Table 18. Global Rituximab Biosimilars Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Rituximab Biosimilars Revenue Market Share by Company (2020-2022)
Table 20. Global Rituximab Biosimilars Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Rituximab Biosimilars Producing Area Distribution and Sales Area
Table 22. Players Rituximab Biosimilars Products Offered
Table 23. Rituximab Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Rituximab Biosimilars Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Rituximab Biosimilars Sales Market Share Geographic Region (2017-2022)
Table 28. Global Rituximab Biosimilars Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Rituximab Biosimilars Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Rituximab Biosimilars Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Rituximab Biosimilars Sales Market Share by Country/Region (2017-2022)
Table 32. Global Rituximab Biosimilars Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Rituximab Biosimilars Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Rituximab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 35. Americas Rituximab Biosimilars Sales Market Share by Country (2017-2022)
Table 36. Americas Rituximab Biosimilars Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Rituximab Biosimilars Revenue Market Share by Country (2017-2022)
Table 38. Americas Rituximab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 39. Americas Rituximab Biosimilars Sales Market Share by Type (2017-2022)
Table 40. Americas Rituximab Biosimilars Sales by Application (2017-2022) & (K Units)
Table 41. Americas Rituximab Biosimilars Sales Market Share by Application (2017-2022)
Table 42. APAC Rituximab Biosimilars Sales by Region (2017-2022) & (K Units)
Table 43. APAC Rituximab Biosimilars Sales Market Share by Region (2017-2022)
Table 44. APAC Rituximab Biosimilars Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Rituximab Biosimilars Revenue Market Share by Region (2017-2022)
Table 46. APAC Rituximab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 47. APAC Rituximab Biosimilars Sales Market Share by Type (2017-2022)
Table 48. APAC Rituximab Biosimilars Sales by Application (2017-2022) & (K Units)
Table 49. APAC Rituximab Biosimilars Sales Market Share by Application (2017-2022)
Table 50. Europe Rituximab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 51. Europe Rituximab Biosimilars Sales Market Share by Country (2017-2022)
Table 52. Europe Rituximab Biosimilars Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Rituximab Biosimilars Revenue Market Share by Country (2017-2022)
Table 54. Europe Rituximab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 55. Europe Rituximab Biosimilars Sales Market Share by Type (2017-2022)
Table 56. Europe Rituximab Biosimilars Sales by Application (2017-2022) & (K Units)
Table 57. Europe Rituximab Biosimilars Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Rituximab Biosimilars Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Rituximab Biosimilars Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Rituximab Biosimilars Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Rituximab Biosimilars Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Rituximab Biosimilars Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Rituximab Biosimilars Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Rituximab Biosimilars Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Rituximab Biosimilars Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Rituximab Biosimilars
Table 67. Key Market Challenges & Risks of Rituximab Biosimilars
Table 68. Key Industry Trends of Rituximab Biosimilars
Table 69. Rituximab Biosimilars Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Rituximab Biosimilars Distributors List
Table 72. Rituximab Biosimilars Customer List
Table 73. Global Rituximab Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Rituximab Biosimilars Sales Market Forecast by Region
Table 75. Global Rituximab Biosimilars Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Rituximab Biosimilars Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Rituximab Biosimilars Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Rituximab Biosimilars Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Rituximab Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Rituximab Biosimilars Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Rituximab Biosimilars Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Rituximab Biosimilars Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Rituximab Biosimilars Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Rituximab Biosimilars Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Rituximab Biosimilars Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Rituximab Biosimilars Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Rituximab Biosimilars Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Rituximab Biosimilars Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Rituximab Biosimilars Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Rituximab Biosimilars Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Rituximab Biosimilars Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Rituximab Biosimilars Revenue Market Share Forecast by Application (2023-2028)
Table 93. Amgen Basic Information, Rituximab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 94. Amgen Rituximab Biosimilars Product Offered
Table 95. Amgen Rituximab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Amgen Main Business
Table 97. Amgen Latest Developments
Table 98. AryoGen Pharmed Basic Information, Rituximab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 99. AryoGen Pharmed Rituximab Biosimilars Product Offered
Table 100. AryoGen Pharmed Rituximab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. AryoGen Pharmed Main Business
Table 102. AryoGen Pharmed Latest Developments
Table 103. Biocad Basic Information, Rituximab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 104. Biocad Rituximab Biosimilars Product Offered
Table 105. Biocad Rituximab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Biocad Main Business
Table 107. Biocad Latest Developments
Table 108. Cadila Pharmaceuticals Basic Information, Rituximab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 109. Cadila Pharmaceuticals Rituximab Biosimilars Product Offered
Table 110. Cadila Pharmaceuticals Rituximab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Cadila Pharmaceuticals Main Business
Table 112. Cadila Pharmaceuticals Latest Developments
Table 113. Celltrion Basic Information, Rituximab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 114. Celltrion Rituximab Biosimilars Product Offered
Table 115. Celltrion Rituximab Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Celltrion Main Business
Table 117. Celltrion Latest Developments
Table 118. Dr Reddy
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)